Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $41.00

Viridian Therapeutics (NASDAQ:VRDN) had its price target upped by analysts at Royal Bank Of Canada from $38.00 to $41.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 42.17% from the stock’s previous close.

A number of other brokerages have also weighed in on VRDN. Needham & Company LLC boosted their price objective on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Wells Fargo & Company increased their target price on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Thursday. Leerink Partners lifted their price target on Viridian Therapeutics from $50.00 to $54.00 and gave the company an “outperform” rating in a research note on Thursday. Wedbush boosted their price target on Viridian Therapeutics from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Weiss Ratings raised Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.00.

Viridian Therapeutics Price Performance

Shares of VRDN stock traded down $0.22 on Thursday, hitting $28.84. 2,414,244 shares of the company’s stock were exchanged, compared to its average volume of 2,154,895. The company has a 50 day moving average of $21.80 and a 200 day moving average of $21.85. The stock has a market cap of $3.27 billion, a P/E ratio of -8.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. Viridian Therapeutics has a 12 month low of $13.18 and a 12 month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21. The firm had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. On average, equities research analysts predict that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Buying and Selling

In other news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP lifted its position in Viridian Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after acquiring an additional 49,808 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in Viridian Therapeutics during the 2nd quarter valued at $25,306,000. Bank of America Corp DE boosted its holdings in Viridian Therapeutics by 17.5% during the 1st quarter. Bank of America Corp DE now owns 1,163,615 shares of the company’s stock worth $22,760,000 after acquiring an additional 173,498 shares during the last quarter. Rice Hall James & Associates LLC purchased a new position in Viridian Therapeutics during the 2nd quarter worth $21,601,000. Finally, Elmind Capital LP purchased a new position in Viridian Therapeutics during the 2nd quarter worth $18,093,182.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Four firms raised their targets and maintained bullish ratings: Truist lifted its target to $42, Wells Fargo to $34, Wedbush to $42, and HC Wainwright to $40. Needham also raised its target to $38. These upgrades point to continued analyst optimism. Truist rating Wells Fargo rating Wedbush rating HC Wainwright rating Needham rating
• Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million versus a $4.72 million consensus. The earnings and revenue beats may support confidence in its progress. Q3 results
• Positive Sentiment: Viridian is targeting broad coverage for its Lumvoa launch in six to nine months and expects to submit an elegrobart biologics license application in the first quarter of 2027. These commercial and regulatory milestones could provide near-term catalysts, though execution remains important. Lumvoa and elegrobart update
• Negative Sentiment: Despite beating estimates, the quarterly loss widened from $0.34 per share a year earlier to $0.81, underscoring that Viridian remains loss-making. A separate commentary also argued the stock may be overvalued even with its new launch, raising valuation concerns after recent optimism. Valuation commentary

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.